Relationship between the TMPRSS2-ERG gene fusion and prostate cancer metastases

Lavin, M. F., Clarke, R. A., Teng, L., Fang, Z. and Gardiner, R. A. (2011). Relationship between the TMPRSS2-ERG gene fusion and prostate cancer metastases. In: Special Issue: Abstracts of the Urological Society of Australia and New Zealand, 64th Annual Scientific Meeting. 64th Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Christchurch, New Zealand, (15-15). 21-24 February 2011.

Author Lavin, M. F.
Clarke, R. A.
Teng, L.
Fang, Z.
Gardiner, R. A.
Title of paper Relationship between the TMPRSS2-ERG gene fusion and prostate cancer metastases
Conference name 64th Annual Scientific Meeting of the Urological Society of Australia and New Zealand
Conference location Christchurch, New Zealand
Conference dates 21-24 February 2011
Proceedings title Special Issue: Abstracts of the Urological Society of Australia and New Zealand, 64th Annual Scientific Meeting   Check publisher's open access policy
Journal name BJU International   Check publisher's open access policy
Place of Publication Oxford, United Kingdom
Publisher Wiley-Blackwell Publishing
Publication Year 2011
Sub-type Published abstract
ISSN 1464-410X
1464-4096
Volume 107
Issue Supp. 1
Start page 15
End page 15
Total pages 1
Collection year 2012
Language eng
Abstract/Summary Genome instability is a major characteristic in the development of cancer. In many tumours, specific chromosome translocations are involved that activate or abrogate individual gene function. In some cases these changes lead to gene fusions such as in prostate cancer (PCa) where fusions between the androgen-regulated prostate-specific TMPRSS2 (transmembrane protease, serine 2) and the ETS family transcription factor genes are common. The most frequently occurring fusion is the TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene-like) which arises by interstitial deletion of chromosomal DNA or by translocation, with up to 20 different fusions described to date. Expression of the androgen-regulated TMPRSS2-ERG fusion has been reported to be present in 40–50% of PCas but its prognostic signifi cance remains unclear. In some cases, expression of TMPRSS2-ERG is associated with a worse prognosis whereas in others with a more favourable outcome. This can be explained to some extent by differences in the cohorts studied and sensitivity in detecting the various fusions. In order for the TMPRSS2-fusions to be prognostic, it can be assumed that they should be expressed commonly in metastases. To investigate this further we availed ourselves of metastatic PCa samples collected as part of an immunotherapy study. These were lymph node metastases in which tumour had completely replaced the nodes. In this exclusively metastatic epithelial environment TMPRSS2-ERG fusion gene expression was observed in 85% of samples significantly higher than that reported for prostate cancer in general. These data suggest that TMPRSS2-ERG expression may be an important prognostic marker in PCa metastases.
Q-Index Code EX
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 24 JAN 2011

Document type: Conference Paper
Collections: UQ Centre for Clinical Research Publications
Non HERDC
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Sun, 13 Feb 2011, 10:05:47 EST